International PFO Consortium


Phase N/A Results N/A

Summary of Purpose

The prevalence of patent foramen ovale (PFO) is about 25% in the general population and approximately 40% in patients who have ischemic stroke of unknown cause (cryptogenic stroke). Given the large number of asymptomatic patients, no primary prevention is currently recommended. On the contrary, secondary prevention is very important. Prospective studies have shown that antithrombotic treatment (ATT) with aspirin...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 11 December 2017.

8 Sep 2008 6 Mar 2009 1 Dec 2021 1 Dec 2021 1 Dec 2017 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Observation: Cohort
  • Perspective: Prospective
  • Sampling: Non-Probability Sample


  • Marie-Luise Mono, MD

  • Krassen Nedeltchev, MD